PURPOSE: This study was conducted to evaluate the efficacy and safety of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC). PATIENTS AND METHODS: Eligibility included histologic or cytologic diagnosis of SCLC, ECOG PS of 0-2, cancer progression following one or two prior chemotherapy or chemo-radiotherapy (CRT) and adequate organ functions. Treatment regimen consisted of a 6-week cycle of sunitinib given as 50mg p.o. daily for 4 weeks followed by 2 weeks off. The primary end point was objective response rate (ORR). RESULTS: From March 2008 to October 2010, 25 patients were enrolled and 24 received treatment. The median age was 64.5 years; 22 patients (92%) were male. Eight patients (33%) displayed sensitive relapse. Seven patients (29%) received CRT and fifteen patients (63%) had received one prior chemotherapy. A median of 1 cycle (range 1-4) of sunitinib was administered, and 23 patients were evaluable for response. Two patients displayed partial response, and seven patients presented stable disease with a ORR of 9% (95% CI, 1-28%). The median progression-free (PFS) and overall survivals were 1.4 months (95% CI, 1.1-1.7) and 5.6 months (95% CI, 3.5-7.7), respectively. The common grade 3 or 4 toxicities included thrombocytopenia (63%), asthenia (29%) and neutropenia (25%). CONCLUSIONS: Although tumor response was noted in 2 patients, the median PFS was short and most patients were unable to tolerate the treatment. At the current dose schedule, sunitinib does not appear to warrant further evaluation.
PURPOSE: This study was conducted to evaluate the efficacy and safety of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC). PATIENTS AND METHODS: Eligibility included histologic or cytologic diagnosis of SCLC, ECOG PS of 0-2, cancer progression following one or two prior chemotherapy or chemo-radiotherapy (CRT) and adequate organ functions. Treatment regimen consisted of a 6-week cycle of sunitinib given as 50mg p.o. daily for 4 weeks followed by 2 weeks off. The primary end point was objective response rate (ORR). RESULTS: From March 2008 to October 2010, 25 patients were enrolled and 24 received treatment. The median age was 64.5 years; 22 patients (92%) were male. Eight patients (33%) displayed sensitive relapse. Seven patients (29%) received CRT and fifteen patients (63%) had received one prior chemotherapy. A median of 1 cycle (range 1-4) of sunitinib was administered, and 23 patients were evaluable for response. Two patients displayed partial response, and seven patients presented stable disease with a ORR of 9% (95% CI, 1-28%). The median progression-free (PFS) and overall survivals were 1.4 months (95% CI, 1.1-1.7) and 5.6 months (95% CI, 3.5-7.7), respectively. The common grade 3 or 4 toxicities included thrombocytopenia (63%), asthenia (29%) and neutropenia (25%). CONCLUSIONS: Although tumor response was noted in 2 patients, the median PFS was short and most patients were unable to tolerate the treatment. At the current dose schedule, sunitinib does not appear to warrant further evaluation.
Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-02
Authors: Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2017-09-14 Impact factor: 11.527
Authors: Maria B Lebron; Laura Brennan; Christopher B Damoci; Marie C Prewett; Marguerita O'Mahony; Inga J Duignan; Kelly M Credille; James T DeLigio; Marina Starodubtseva; Michael Amatulli; Yiwei Zhang; Kaben D Schwartz; Douglas Burtrum; Paul Balderes; Kris Persaud; David Surguladze; Nick Loizos; Keren Paz; Helen Kotanides Journal: Cancer Biol Ther Date: 2014-06-12 Impact factor: 4.742
Authors: Neal E Ready; Herbert H Pang; Lin Gu; Gregory A Otterson; Sachdev P Thomas; Antonius A Miller; Maria Baggstrom; Gregory A Masters; Stephen L Graziano; Jeffrey Crawford; Jeffrey Bogart; Everett E Vokes Journal: J Clin Oncol Date: 2015-03-02 Impact factor: 44.544
Authors: Benjamin Carlisle; Nadine Demko; Georgina Freeman; Amanda Hakala; Nathalie MacKinnon; Tim Ramsay; Spencer Hey; Alex John London; Jonathan Kimmelman Journal: J Natl Cancer Inst Date: 2015-11-07 Impact factor: 13.506